Wednesday, May 3, 2023
8:00 - 9:00  
9:00 - 9:15

Introduction to the Programme

Harley Eisman, MD, Co-Founder, Hereditary Breast and Ovarian Cancer Foundation, Montréal, QC, Canada

William Foulkes, MBBS, PhD, Director, Program in Cancer Genetics, McGill University, Montréal, QC, Canada

The breast cancer genes: How to implement what we know and what to expect next
9:15 - 10:45

CHAIR: Britta Weigelt, PhD, Memorial Sloan Kettering Cancer Center, New York, NY, USA

9:15 - 9:35

CanRisk: personalising cancer risk prediction for prevention and early detection

Antonis Antoniou, PhD, University of Cambridge, Cambridge, UK

9:35 - 9:55

The breast cancer susceptibility gene scorecard: What is in, what is out and what is left to find?

Clare Turnbull, MD, PhD, MFPH, Institute of Cancer Research, London, UK

9:55 - 10:05

Finding new causes of hereditary breast cancer: resolving the role of inherited promoter hypermethylation in known hereditary breast cancer genes and mutations in non-coding regions of BRCA1, BRCA2 and PALB2

Ian G Campbell, PhD, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia

10:05 - 10:15

Multiplexed assays of variant effect for all possible missense alterations located in the DNA Binding Domain of BRCA2

Fergus Couch, PhD, Fergus Couch, PhD, Mayo Clinic, Rochester, MN, United States

10:17 - 10:20

Poster # P059: Exome sequencing identifies novel susceptibility genes and defines the contribution of coding variants to breast cancer risk

Naomi Wilcox, PhD student, University of Cambridge, Cambridge, UK

10:20 - 10:23

Poster # P083: Universal whole genome tumour and germline sequencing of newly diagnosed breast cancer

Ian G Campbell, PhD, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia

10:25 - 10:45

Question and discussion period (all speakers)

10:45 - 11:15  
New approaches to the early diagnosis of hereditary cancers
11:15 - 12:45

CHAIR: Alan Spatz, MD, MSc, McGill University, Montréal, QC, Canada

11:15 - 11:35

Li-Fraumeni as a case study of the effect of early diagnosis on outcomes

David Malkin, MD, FRCPC, The Hospital for Sick Children (SickKids), Toronto, ON, Canada

11:35 - 11:55

Hereditary Cancer Surveillance Using Cell-free DNA Sequencing

Trevor Pugh, PhD, FACMG, Ontario Institute for Cancer Research (OICR), Toronto, ON, Canada

11:55 - 12:05

Increase in tumor DNA testing during nationwide implementation of the Tumor-First workflow to optimize identification of heredity in epithelial ovarian cancer

Vera M. Witjes, PhD candidate, Radboud University Medical Center, Nijmegen, The Netherlands

12:05 - 12:15

MRI surveillance and breast cancer mortality in BRCA1 and BRCA2 mutation carriers

Steven Narod, MD, Women’s College Research Institute, Women’s College Hospital, Toronto, ON, Canada

12:17 - 12:20

Somatic testing lags far behind germline testing in patients with epithelial ovarian cancer; a missed opportunity

Kayla Ostiller, MD, Kaiser Permanente San Francisco, CA, United States

12:20 - 12:23

Facilitated cascade testing for families with identified variants associated with hereditary gynecologic cancers

Sarah S. Lee, MD, NYU Langone Health, New York, NY, United States

12:25 - 12:45

Question and discussion period (all speakers)

12:45 - 14:15  
Special Interest Groups (SIGs)
14:15 - 15:45

Moderated 90-minute interactive discussions with the aim of fostering bilateral knowledge transfer. Choice of one of the following 3 SIGs.

SIG 1:

Other BRCA-associated Cancers (pancreas and prostate): Germline Testing, Early Detection and Targeted Cancer Therapies

This session will focus on the evidence and recommendations for 1) germline testing in incident cases of pancreatic and prostate cancers, 2) surveillance of germline BRCA2, BRCA1 and PALB2 mutation carriers for early detection of pancreatic and prostate cancers, and 3) targeted therapies in patients with pancreatic and prostate cancers driven by BRCA2, BRCA1 or PALB2 mutations. Attendees will be encouraged to send in questions relating to these topics in advance for discussion at the SIG.

  • George Zogopoulos, MD, PhD, McGill University Health Centre, Montréal, QC, Canada

  • Daniel Vesprini, MD, MSc, FRCPC, Sunnybrook Odette Cancer Centre, Toronto, ON, Canada

SIG 2:

Professional ethical duty and liability in a context of increasing decentralization and de-specialisation of genetic tests

The use of genetic tests for precision oncology has increased considerably, propelled by rapid scientific advances in genomics and the popularity of direct-to-consumer services. To meet this increasing demand, we have seen emerge a phenomenon of decentralization and de-specialisation of genetic testing in healthcare systems. The current session will cover some of the principal issues raised by this new genetic testing context and propose innovative solutions to address them.

  • Yann Joly, PhD, AdE McGill University, Montréal, QC, Canada (session lead)

  • David J. Peloquin, JD, Ropes & Gray, Boston, MA, USA

  • Yvonne Bombard, PhD, BSc, Li Ka Shing Knowledge Institute, St Michael’s Hospital, Toronto, ON, Canada

SIG 3:

Cancer Concerns for Transgender and Gender Diverse People

In this session, the three presenters will lead a discussion regarding cancer risks among transgender / gender diverse (TGD) people along with barriers to cancer surveillance and treatment, including considerations regarding BRCA testing for breast cancer risk in TGD people. The discussion will include risks associated with typical gender affirming medical interventions and risks associated with the myriad barriers to cancer care for TGD people. Attendees will be encouraged to submit questions in advance to help inform the conversation.

  • Joshua D. Safer, MD, Mount Sinai Center for Transgender Medicine and Surgery, Mount Sinai Health System, New York, NY, USA (session lead)

  • Sharon Bober – PhD, Dana-Farber Cancer Institute/Harvard Medical School, Boston, MA, USA

15:45 - 16:15  
Special Round Table: Disparities in Hereditary Cancer Genetics – What are we doing to improve the situation?
16:15 - 17:45

Lawrence Brody, PhD, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD, USA;
Laurence Baret, MA, MSc, CCGC, CGC, McGill University, Montréal, QC, Canada

Tuya Pal, MD, Vanderbilt – Ingram Cancer Center, Nashville, TN, USA

Yvonne Bombard, PhD, BSc, Li Ka Shing Knowledge Institute, St Michael’s Hospital, Toronto, ON, Canada

Funmi Olopade, MD, FACP, OON, Center for Clinical Cancer Genetics, University of Chicago Medicine, Chicago, IL, USA

Grace-Ann Fasaye, ScM, CGC, Genetics Branch of the Center for Cancer Research at the National Cancer Institute (NCI), Bethesda, MD, USA